Royalty Pharma plc (NASDAQ:RPRX) is among the 11 best performing biotech stocks in 2025. In Q2, it saw significant growth, with Portfolio Receipts up 20% to $727 million and Royalty Receipts up 11%. The acquisition of RP Management, LLC, streamlined operations, while investments in oncology and new funding arrangements enhanced portfolio diversification.

Royalty Pharma plc (RPRX) recently committed up to $300 million to Zenas Biopharma’s obexelimab program, showcasing its dedication to supporting innovative pipeline products. While RPRX shows investment potential, certain AI stocks may offer greater upside potential and lower downside risk. Consider exploring undervalued AI stocks for potential growth opportunities.

Read more at Yahoo Finance: Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program